Confirmatory Dose Finding Study of 2 Dosages of CHF 4226 pMDI (Carmoterol) in Patients With COPD

Phase 2

Completed

• Conditions: Chronic Obstructive Pulmonary Disease
• Interventions: Drug: carmoterol (CHF 4226); Drug: placebo; Drug: salmeterol

• Registration Number: NCT00640484
• Lead Sponsor: Chiesi Farmaceutici S.p.A.

Brief Summary

The purpose of this study is to confirm the dose of CHF 4226 (carmoterol) that should be given once a day to patients with COPD in order for the effect to last for 24 hours.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2008-03-18
• Study First Submitted QC: 2008-03-18
• Study First Posted: 2008-03-21
• Study Start: 2008-04
• Primary Completion: 2008-10
• Study Completion: 2008-10
• Status Verified: 2010-08
• Disposition First Submitted: 2010-08-18
• Disposition First Submitted QC: 2010-08-18
• Disposition First Posted: 2010-08-20
• Last Update Submitted: 2010-08-24
• Last Update Posted: 2010-08-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 57

Inclusion Criteria

• Signed IRB approved Informed Consent form

• Male or non-pregnant female, 40 -75 years old, inclusive

• Current or past cigarette smoking history of at least 15 pack-years

• Clinical diagnosis of COPD in accordance with recommendations of the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO) Global Initiative for Chronic Obstructive Lung Disease (GOLD)

• Patient meets following requirements after FEV1 albuterol reversibility test (i.e., 30 minutes after 200μg (metered dose) albuterol MDI):

  • FEV1/FVC < 70%
  • FEV1 is at least 0.9L
  • FEV1 30% - 80%, inclusive, of patient's predicted normal value; ∆FEV1 > 5% of pre-albuterol value
  • If ∆FEV1 < 5% of pre-albuterol value, requirement must be met after retesting during run-in period, at least 24 hours prior to Period 1/Visit 1.

Exclusion Criteria

• History of asthma

• Blood eosinophil count > 500/microliters

• History of allergic rhinitis or atopy

• COPD exacerbation or lower respiratory tract infection within 8 weeks prior to screening, or during run-in period, that resulted in use of an antibiotic, or oral or parenteral corticosteroids

• Inhaled corticosteroid that has been initiated, or effective dose has been changed, within 4 weeks prior to screening or during run-in period

• Uncontrolled cardiovascular (e.g., uncontrolled hypertension), respiratory, hematologic, immunologic, renal, neurologic, hepatic, endocrine (e.g., uncontrolled diabetes mellitus) or other disease, or any condition that might, in Investigator's judgment, place patient at undue risk or potentially compromise study results or interpretation

• History of coronary artery disease, cerebrovascular disease, cardiac arrhythmias

• Lung cancer or history of lung cancer

• Active cancer or history of cancer with < 5 years disease free survival time (with or without evidence of local recurrence or metastases). Localized basal cell carcinoma (without metastases) of skin is acceptable.

• Serum potassium value ≤ 3.5 mEq/L or > 5.5mEq/L and/or fasting serum glucose value ≥ 140 mg/dL

• Abnormal QTcF interval value in Screening visit ECG test (i.e., > 450 msec in males or > 470 msec in females)

• Cor Pulmonale

• Long term oxygen therapy, i.e., > 16 hours/24-hour period, every day, unless patient resides at elevation > 4000ft

• Use of any of the following medications prior to Screening, without meeting specified minimum washout period:

  • Long acting anti-cholinergic agent (i.e., tiotropium): 7 days
  • Short acting anti-cholinergics: 8 hours
  • Fixed combinations of β2-agonists and inhaled corticosteroids: 48 hours
  • Fixed combinations of an anti-cholinergic and short acting β2-agonist: 8 hours

• Long-acting β2-agonists: 48 hours

• Short acting β2-agonists (other than those prescribed in the study): 6 hours

• Theophylline and other xanthines: 1 week

• Parenteral or oral corticosteroids: 1 month

• Patient has taken any non-permitted medication

• Patient has received live-attenuated virus vaccination within two weeks prior to screening or during run-in (inactivated Influenza vaccination is acceptable if given > 48 hours prior to Screening)

• Known intolerance/hypersensitivity to β2-adrenergic agonists, propellant gases/excipients

• Patient is pregnant or lactating female, or female at risk of pregnancy (i.e., not using adequate contraceptive method: surgical sterilization [e.g., bilateral tubal ligation], hormonal contraception [implantable, patch, oral], IUD, and double-barrier methods [any double combination of: male or female condom with spermicidal gel, diaphragm, sponge, cervical cap]).

• Patient is mentally or legally incapacitated

• Patient has participated in another investigational study within 30 days prior to screening

• Abuse of alcohol or other substances

• Patient does not maintain regular day/night, waking/sleeping cycles (e.g., night shift worker)

• Patient is potentially non-compliant or unable to perform required protocol outcome measurements

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
B	carmoterol (CHF 4226)	CHF 4226 (carmoterol) 4 μg once a day, in the morning
A	carmoterol (CHF 4226)	CHF 4226 (carmoterol) 2 μg once a day, in the morning
C	placebo	placebo once a day, in the morning
D	salmeterol	salmeterol 50 μg twice daily, in the morning and in the evening

Primary Outcome Measures

Name	Time	Method
FEV1 AUC0-24 standardized by time	on Day 15 (after 14 days of dosing)

Secondary Outcome Measures

Name	Time	Method
blood pressure	at the beginning and end of each of the four 14-day treatment periods
FEV1 percent change	30 min, 1, 2 ,3, 4, 6, 10, 12, 14, 16, 22, 23, and 24 hrs post dose at Visit 2 at all treatment periods
FEV1(L)	30 min, 1, 2 ,3, 4, 6, 10, 12, 14, 16, 22, 23, and 24 hrs post dose at Visit 2 at all treatment periods
heart rate	at the beginning and end of each of the four 14-day treatment periods

Trial Locations

Locations (15)

Spartanburg Medical Research; 🇺🇸 Spartanburg, South Carolina, United States

UCLA David Geffen School of Medicine; 🇺🇸 Los Angeles, California, United States

Horizon Clinical Research Associates, PLLC; 🇺🇸 Gilbert, Arizona, United States

University Clinical Research - DeLand, LLC; 🇺🇸 DeLand, Florida, United States

Pulmonary Medicine and Critical Care; 🇺🇸 Austell, Georgia, United States

Sneeze, Wheeze & Itch Associates, LLC; 🇺🇸 Normal, Illinois, United States

Commonwealth BioMedical Research; 🇺🇸 Madisonville, Kentucky, United States

North Carolina Clinical Research; 🇺🇸 Raleigh, North Carolina, United States

Clinical Research Institute of Southern Oregon, PC; 🇺🇸 Medford, Oregon, United States

Reichman Associates; 🇺🇸 Sugar Land, Texas, United States

Pulmonary Associates, PA; 🇺🇸 Phoenix, Arizona, United States

New Horizons Clinical Research; 🇺🇸 Cincinnati, Ohio, United States

Lynn Health Science Institute; 🇺🇸 Oklahoma City, Oklahoma, United States

Asthma Allergy Associates; 🇺🇸 Portland, Oregon, United States

University of Utah; 🇺🇸 Salt Lake City, Utah, United States